Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Spero Therapeutics (SPRO) Income from Continuing Operations (2016 - 2025)

Spero Therapeutics (SPRO) has disclosed Income from Continuing Operations for 10 consecutive years, with 6850000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Income from Continuing Operations rose 61.3% year-over-year to 6850000.0, compared with a TTM value of 43118000.0 through Sep 2025, down 1552.76%, and an annual FY2024 reading of 68626000.0, down 400.73% over the prior year.
  • Income from Continuing Operations was 6850000.0 for Q3 2025 at Spero Therapeutics, down from 1704000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 51187000.0 in Q4 2023 and bottomed at 30135000.0 in Q1 2022.
  • Average Income from Continuing Operations over 5 years is 10553210.53, with a median of 13867000.0 recorded in 2025.
  • The sharpest move saw Income from Continuing Operations soared 181.17% in 2022, then tumbled 684.97% in 2024.
  • Year by year, Income from Continuing Operations stood at 27426000.0 in 2021, then skyrocketed by 181.17% to 22262000.0 in 2022, then soared by 129.93% to 51187000.0 in 2023, then tumbled by 140.43% to 20697000.0 in 2024, then surged by 66.9% to 6850000.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for SPRO at 6850000.0 in Q3 2025, 1704000.0 in Q2 2025, and 13867000.0 in Q1 2025.